Taxanes (docetaxel and paclitaxel) are among the most commonly prescribed anticancer drugs approved for the treatment of metastatic or locally advanced breast, non-small cell lung, prostate, gastric, head and neck, and ovarian cancers, as well as in the adjuvant setting for operable node-positive breast cancers. Although the true incidence of dermatological adverse events (AEs) in patients receiving taxanes is not known, and has never been prospectively analysed, they clearly represent one of the major AEs associated with these agents. With an increase in the occurrence of cutaneous AEs during treatment with novel targeted and immunological therapies when used in combination with taxanes, a thorough understanding of reactions attributable to this class is imperative. Moreover, identification and management of dermatological AEs is critical for maintaining the quality of life in cancer patients and for minimizing dose modifications of their antineoplastic regimen. This analysis represents a systematic review of the dermatological conditions reported with the use of these drugs, complemented by experience at comprehensive cancer centres. The conditions reported herein include skin, hair, and nail toxicities. Lastly, we describe the dermatological data available for the new, recently FDA-and EMA- approved, solvent-free nab-paclitaxel.

This article has an accompanying continuing medical education activity, also eligible for MOC credit, on page e19. Learning Objective: Upon completion of this CME activity successful learners will be able to (1) evaluate the probability of a venous thromboembolism (VTE) in patients with newly diagnosed pancreatic ductal adenocarcinoma (PDAC); (2) identify the risk factors for VTE in patients with PDAC; and (3) assess the impact of VTE on survival in patients with PDAC. Venous Thromboembolism and Pancreatic CancerThe BACAP-VTE Study : pancreatic cancer patients prospectively followed-up from time of enrollment until last visit or death 152 patients (20.79%) developed a VTE during a median follow-up of 19.3 months Patients developing VTE during follow-up had lower PFS (HR 1.74, 95%CI 1.19-2.54, P=.004) Patients developing VTE during follow-up had lower OS (HR 2.02, 95%CI 1.57-2.60, P<.001).

No abstract

No abstract

This study provided evidence for the manageable safety profile and feasibility of using the novel triplet combination of pazopanib, irinotecan, and cetuximab in patients with refractory mCRC. Further large-scale Phase II studies are warranted.